Department of Medical Oncology, Institut Bergonié, 229 cours de l'Argonne, 33076 Bordeaux Cedex, France.
Cancer Chemother Pharmacol. 2010 May;66(1):197-202. doi: 10.1007/s00280-010-1275-3. Epub 2010 Feb 25.
Angiogenesis plays a crucial role in metastatic progression of soft tissue sarcomas (STS). Endothelial cells are the primary target of metronomic chemotherapy. We report the safety and the efficacy of metronomic chemotherapy in metastatic STS patients.
The medical charts of 26 metastatic STS patients treated at Institut Bergonie (Bordeaux, France) with metronomic etoposide (100 mg/day orally for 21 consecutive days, repeated every 4 weeks) were reviewed by two independent investigators.
Median age was 49. All but three patients received prior treatment with doxorubicin and/or ifosfamide. One patient (4%) had partial response and 11 patients (42%) had stable disease for more than 24 weeks. The 6-month and the 1-year progression-free survival rates were 42% [95% CI: 23; 61] and 23% [95% CI: 7; 39], respectively. The 6-month and the 1-year overall survival rates were 69% [95% CI: 51; 87] and 31% [95% CI: 13; 49], respectively. Two patients experienced grade 4 febrile neutropenia and one of them died of sepsis.
In this series, metronomic etoposide was associated with significant clinical activity in STS. Further prospective investigations are necessary to identify those patients who are more likely to benefit from this strategy.
血管生成在软组织肉瘤（STS）的转移进展中起着关键作用。内皮细胞是节拍化疗的主要靶点。我们报告了节拍化疗在转移性 STS 患者中的安全性和疗效。
通过两位独立研究者对 Institut Bergonie（波尔多，法国）接受节拍依托泊苷（100mg/天，口服，连续 21 天，每 4 周重复）治疗的 26 例转移性 STS 患者的病历进行了回顾。
中位年龄为 49 岁。除了 3 例患者外，所有患者均接受过多柔比星和/或异环磷酰胺治疗。1 例患者（4%）有部分缓解，11 例患者（42%）疾病稳定超过 24 周。6 个月和 1 年无进展生存率分别为 42%（95%CI：23%；61%）和 23%（95%CI：7%；39%）。6 个月和 1 年总生存率分别为 69%（95%CI：51%；87%）和 31%（95%CI：13%；49%）。2 例患者出现 4 级发热性中性粒细胞减少症，其中 1 例死于败血症。
在本系列中，节拍依托泊苷与 STS 显著的临床活性相关。需要进一步的前瞻性研究来确定那些更有可能从这种策略中获益的患者。
